All In Biotech

Drug Trial Radar · NCT06444880

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 9, 2024

Primary completion

Jul 31, 2027

Study completion Jul 31, 2028

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regeneron Pharmaceuticals
First posted
Jun 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).

Conditions

  • SMARCB1-Deficient Malignancies
  • Epithelioid Sarcoma
  • Renal Medullary Carcinoma

Interventions

  • UbamatamabDrug

    Given by IV

  • CemiplimabDrug

    Given by IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and adverse events (AEs)Time frame: Through study completion; an average of 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.